Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMOD plus standard care for severe sepsis
ACTRN12609000001291Phase 3Not yet recruiting
- Sponsor
- Pars Rus
- Start
- Dec 2008
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of IMOD in sepsis (2 arms), sponsored by Pars Rus. Primary endpoint: mortality at 28 days. Planned start Dec 2008; status: not yet recruiting.
02
Drugs
IMOD
03
Conditions
sepsis
Beyond the preview
Go deeper on ACTRN12609000001291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000001291.